Categories Annual ReportsCorporate GovernanceDefault CalendarFeatured DocumentsPresentationsProxy Statements Year None2024202320222021202020192018201720162015201420132012201120102009200820072006 Title Supernus Schedules Conference Call to Present Results of Phase IIb Clinical Trial of SPN-812 in Children with ADHD Supernus Receives FDA Tentative Approval for Expanded Label of Trokendi XR® to Include Migraine Prophylaxis in Adults Supernus Announces Resignation of Dr. James Barrett from Board of Directors; Charles W. Newhall, III Elected Chairman Supernus Announces Second Quarter 2016 Financial Results 2015 Annual Report Supernus to Host Second Quarter 2016 Earnings Conference Call Supernus Announces Issuance of Seventh U.S. Patent Protecting Oxtellar XR® View Presentation Supernus Provides Update on Trokendi XR® Migraine sNDA and Reiterates Guidance Supernus Announces Issuance of Sixth U.S. Patent Protecting Oxtellar XR® Pagination First page « first Previous page ‹ previous … Page 5 Page 6 Page 7 Page 8 Current page 9 Page 10 Page 11 Page 12 Page 13 … Next page next › Last page last »